Boston Scientific Corporation Stock Price, News & Analysis (NYSE:BSX)

$28.26 -0.02 (-0.07 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$28.26
Today's Range$28.37 - $28.14
52-Week Range$19.67 - $29.93
Volume5.15 million shs
Average Volume7.18 million shs
Market Capitalization$38.80652 billion
P/E Ratio23.16
Dividend YieldN/A
Beta1

About Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.


Industry, Sector and Symbol:
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Sector: Medical
  • Symbol: NYSE:BSX
  • CUSIP: 10113710
  • Web: www.bostonscientific.com
Debt:
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 0.72%
  • Quick Ratio: 0.50%
Price-To-Earnings:
  • Trailing P/E Ratio: 23.16
  • Forward P/E Ratio: 22.61
  • P/E Growth: 2.18
Sales & Book Value:
  • Annual Sales: $8.386 billion
  • Price / Sales: 4.63
  • Cash Flow: $1.73 per share
  • Price / Cash: 16.31
  • Book Value: $4.94 per share
  • Price / Book: 5.72
Profitability:
  • Trailing EPS: $0.61
  • Net Income: $347 million
  • Net Margins: 9.55%
  • Return on Equity: 23.60%
  • Return on Assets: 9.24%
Misc:
  • Employees: 27,000
  • Outstanding Shares: 1,373,200,000
 

Frequently Asked Questions for Boston Scientific Corporation (NYSE:BSX)

What is Boston Scientific Corporation's stock symbol?

Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific Corporation's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting analysts' consensus estimates of $0.31. The medical equipment provider had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The firm's revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm earned $0.27 earnings per share. View Boston Scientific Corporation's Earnings History.

When will Boston Scientific Corporation make its next earnings announcement?

Boston Scientific Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Boston Scientific Corporation.

What guidance has Boston Scientific Corporation issued on next quarter's earnings?

Boston Scientific Corporation issued an update on its fourth quarter earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $0.32-0.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.34. The company issued revenue guidance of $2.345-2.375, compared to the consensus revenue estimate of $2.32 billion.

Where is Boston Scientific Corporation's stock going? Where will Boston Scientific Corporation's stock price be in 2017?

17 equities research analysts have issued twelve-month price objectives for Boston Scientific Corporation's stock. Their forecasts range from $28.00 to $36.00. On average, they expect Boston Scientific Corporation's share price to reach $31.11 in the next year. View Analyst Ratings for Boston Scientific Corporation.

What are Wall Street analysts saying about Boston Scientific Corporation stock?

Here are some recent quotes from research analysts about Boston Scientific Corporation stock:

  • 1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. In the past three months, Boston Scientific has been trading above the broader industry. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, the recall of the company's Lotus range of heart devices is expected to hamper sales through 2017." (10/30/2017)
  • 2. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 3. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
  • 4. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)

Who are some of Boston Scientific Corporation's key competitors?

Who are Boston Scientific Corporation's key executives?

Boston Scientific Corporation's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer (Age 52)
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President (Age 51)
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa (Age 64)
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President (Age 66)
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management (Age 53)
  • Edward F. Mackey, Executive Vice President - Operations (Age 54)
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer (Age 60)
  • Michael P. Phalen, Executive Vice President; President - MedSurg (Age 57)
  • Desiree Ann Ralls-Morrison, Senior Vice President, General Counsel, Corporate Secretary (Age 51)
  • Wendy Carruthers, Senior Vice President - Human Resources (Age 48)

Who owns Boston Scientific Corporation stock?

Boston Scientific Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (3.81%), Janus Henderson Group PLC (2.67%), Artisan Partners Limited Partnership (2.64%), Bank of New York Mellon Corp (1.33%), Orbimed Advisors LLC (0.98%) and Evercore Trust Company N.A. (0.82%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific Corporation.

Who sold Boston Scientific Corporation stock? Who is selling Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, JPMorgan Chase & Co., APG Asset Management N.V., Boston Partners, Orbimed Advisors LLC, Point72 Asset Management L.P. and Bank of New York Mellon Corp. Company insiders that have sold Boston Scientific Corporation company stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific Corporation.

Who bought Boston Scientific Corporation stock? Who is buying Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., American Century Companies Inc., Sirios Capital Management L P, Teachers Retirement System of The State of Kentucky, Associated Banc Corp, State of Wisconsin Investment Board, Russell Investments Group Ltd. and Stifel Financial Corp. View Insider Buying and Selling for Boston Scientific Corporation.

How do I buy Boston Scientific Corporation stock?

Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific Corporation's stock price today?

One share of Boston Scientific Corporation stock can currently be purchased for approximately $28.26.

How big of a company is Boston Scientific Corporation?

Boston Scientific Corporation has a market capitalization of $38.80652 billion and generates $8.386 billion in revenue each year. The medical equipment provider earns $347 million in net income (profit) each year or $0.61 on an earnings per share basis. Boston Scientific Corporation employs 27,000 workers across the globe.

How can I contact Boston Scientific Corporation?

Boston Scientific Corporation's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific Corporation (NYSE BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  562 (Vote Outperform)
Underperform Votes:  527 (Vote Underperform)
Total Votes:  1,089
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Boston Scientific Corporation (NYSE:BSX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 13 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $31.11 (10.07% upside)

Consensus Price Target History for Boston Scientific Corporation (NYSE:BSX)

Price Target History for Boston Scientific Corporation (NYSE:BSX)

Analysts' Ratings History for Boston Scientific Corporation (NYSE:BSX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Royal Bank Of CanadaReiterated RatingBuy$31.00N/AView Rating Details
10/31/2017SunTrust Banks, Inc.Set Price TargetBuy$34.00N/AView Rating Details
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$30.00 -> $32.00N/AView Rating Details
10/24/2017Canaccord GenuityInitiated CoverageBuy -> Buy$36.00N/AView Rating Details
10/3/2017Needham & Company LLCReiterated RatingBuy$32.00LowView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
9/7/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
8/9/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
7/28/2017Cowen and CompanyReiterated RatingBuy$31.00 -> $32.00LowView Rating Details
6/28/2017J P Morgan Chase & CoReiterated RatingOverweight$27.00 -> $31.00LowView Rating Details
6/28/2017Barclays PLCBoost Price TargetOverweight -> Overweight$30.00 -> $31.00LowView Rating Details
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 -> $28.50LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/6/2016Citigroup Inc.Boost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016Benchmark Co.Boost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of America CorporationReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche Bank AGReiterated RatingHoldN/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Boston Scientific Corporation (NYSE:BSX)

Earnings by Quarter for Boston Scientific Corporation (NYSE:BSX)

Earnings History by Quarter for Boston Scientific Corporation (NYSE BSX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$0.34N/AView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.21 billion$2.22 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Boston Scientific Corporation (NYSE:BSX)
2017 EPS Consensus Estimate: $1.26
2018 EPS Consensus Estimate: $1.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.31$0.31
Q3 20176$0.30$0.32$0.31
Q4 20175$0.31$0.35$0.34
Q1 20183$0.30$0.33$0.31
Q2 20183$0.36$0.37$0.36
Q3 20184$0.34$0.37$0.35
Q4 20183$0.38$0.40$0.39
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Boston Scientific Corporation (NYSE:BSX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Boston Scientific Corporation (NYSE BSX)

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 90.68%
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Insider Trades by Quarter for Boston Scientific Corporation (NYSE BSX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.00View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.00View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.00View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.40View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.00View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.00View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.12View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.28View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Boston Scientific Corporation (NYSE BSX)

Source:
DateHeadline
 Analysts Anticipate Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.35 Billion Analysts Anticipate Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.35 Billion
www.americanbankingnews.com - November 18 at 8:24 AM
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and DickinsonThe Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
finance.yahoo.com - November 17 at 2:40 PM
Zacks: Analysts Expect Boston Scientific Corporation (BSX) Will Announce Earnings of $0.34 Per ShareZacks: Analysts Expect Boston Scientific Corporation (BSX) Will Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - November 16 at 8:30 AM
Boston Scientific (BSX) a Buy on Solid Earnings GrowthBoston Scientific (BSX) a Buy on Solid Earnings Growth
investorplace.com - November 14 at 11:54 AM
Boston Scientific To Participate In Piper Jaffray 29th Annual Healthcare ConferenceBoston Scientific To Participate In Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 14 at 12:10 AM
Stocks Generating Improved Relative Strength: Boston ScientificStocks Generating Improved Relative Strength: Boston Scientific
finance.yahoo.com - November 10 at 12:26 PM
ETFs with exposure to Boston Scientific Corp. : November 10, 2017ETFs with exposure to Boston Scientific Corp. : November 10, 2017
finance.yahoo.com - November 10 at 12:26 PM
Expect Boston Scientifics Rhythm Management Growth To Slow DownExpect Boston Scientific's Rhythm Management Growth To Slow Down
finance.yahoo.com - November 9 at 6:01 PM
FY2018 Earnings Forecast for Boston Scientific Corporation Issued By Oppenheimer Holdings (BSX)FY2018 Earnings Forecast for Boston Scientific Corporation Issued By Oppenheimer Holdings (BSX)
www.americanbankingnews.com - November 9 at 2:24 PM
Boston Scientific To Participate In Stifel 2017 Healthcare Conference - PR Newswire (press release)Boston Scientific To Participate In Stifel 2017 Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 8 at 7:35 PM
Boston Scientific To Participate In Stifel 2017 Healthcare ConferenceBoston Scientific To Participate In Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 7:35 PM
New Societal Guidelines Recommend Subcutaneous Implantable Cardioverter-Defibrillator for Patients with Ventricular Arrhythmias at Risk of Sudden Cardiac DeathNew Societal Guidelines Recommend Subcutaneous Implantable Cardioverter-Defibrillator for Patients with Ventricular Arrhythmias at Risk of Sudden Cardiac Death
finance.yahoo.com - November 8 at 7:35 PM
Analysts Set Expectations for Boston Scientific Corporations FY2017 Earnings (BSX)Analysts Set Expectations for Boston Scientific Corporation's FY2017 Earnings (BSX)
www.americanbankingnews.com - November 8 at 12:30 PM
Boston Scientific Corp. :BSX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Boston Scientific Corp. :BSX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 7:41 PM
Boston Scientific (BSX) a Buy on Strong Earnings GrowthBoston Scientific (BSX) a Buy on Strong Earnings Growth
investorplace.com - November 7 at 3:34 PM
Boston Scientific To Participate In 26th Annual Credit Suisse Healthcare ConferenceBoston Scientific To Participate In 26th Annual Credit Suisse Healthcare Conference
finance.yahoo.com - November 6 at 5:56 PM
Boston Scientific Corporation (BSX) Given Average Rating of "Buy" by AnalystsBoston Scientific Corporation (BSX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 11:44 AM
Head-To-Head Comparison: Boston Scientific Corporation (BSX) versus Its CompetitorsHead-To-Head Comparison: Boston Scientific Corporation (BSX) versus Its Competitors
www.americanbankingnews.com - November 4 at 11:59 AM
Contrasting Boston Scientific Corporation (BSX) and Its PeersContrasting Boston Scientific Corporation (BSX) and Its Peers
www.americanbankingnews.com - November 2 at 7:22 PM
Boston Scientific Corporation (BSX) EVP Timothy A. Pratt Sells 10,000 SharesBoston Scientific Corporation (BSX) EVP Timothy A. Pratt Sells 10,000 Shares
www.americanbankingnews.com - November 2 at 5:40 PM
Analyzing Boston Scientific Corporation (BSX) and Its PeersAnalyzing Boston Scientific Corporation (BSX) and Its Peers
www.americanbankingnews.com - November 2 at 5:30 PM
Boston Scientific Improved Its 2017 GuidanceBoston Scientific Improved Its 2017 Guidance
finance.yahoo.com - November 2 at 5:29 PM
What’s Driving Boston Scientific’s Recent Bullish Trend?What’s Driving Boston Scientific’s Recent Bullish Trend?
finance.yahoo.com - November 2 at 5:29 PM
Five-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin TherapyFive-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy
finance.yahoo.com - November 2 at 5:29 PM
Key Takeaways From Boston Scientifics Q3Key Takeaways From Boston Scientific's Q3
finance.yahoo.com - November 2 at 5:29 PM
Wall Street’s Views on Boston Scientific after Its 3Q17 EarningsWall Street’s Views on Boston Scientific after Its 3Q17 Earnings
finance.yahoo.com - November 1 at 5:33 PM
Wall Street’s Views on Boston Scientific after Its 3Q17 EarningsWall Street’s Views on Boston Scientific after Its 3Q17 Earnings
finance.yahoo.com - November 1 at 5:33 PM
Boston Scientific’s 3Q17 Sales Exceeded Wall Street EstimatesBoston Scientific’s 3Q17 Sales Exceeded Wall Street Estimates
finance.yahoo.com - November 1 at 5:33 PM
Boston Scientific’s 3Q17 Sales Exceeded Wall Street EstimatesBoston Scientific’s 3Q17 Sales Exceeded Wall Street Estimates
finance.yahoo.com - November 1 at 5:33 PM
Boston Scientific’s 3Q17 Earnings Meets Analysts Estimates, Tops ProfitsBoston Scientific’s 3Q17 Earnings Meets Analysts Estimates, Tops Profits
finance.yahoo.com - November 1 at 5:33 PM
Boston Scientific’s 3Q17 Earnings Meets Analysts Estimates, Tops ProfitsBoston Scientific’s 3Q17 Earnings Meets Analysts Estimates, Tops Profits
finance.yahoo.com - November 1 at 5:33 PM
Boston Scientific Corporation (BSX) Given a $34.00 Price Target by SunTrust Banks, Inc. AnalystsBoston Scientific Corporation (BSX) Given a $34.00 Price Target by SunTrust Banks, Inc. Analysts
www.americanbankingnews.com - November 1 at 3:22 PM
RSI Alert: Boston Scientific (BSX) Now OversoldRSI Alert: Boston Scientific (BSX) Now Oversold
www.nasdaq.com - October 31 at 5:55 PM
Boston Scientifics (BSX) Investor Update On Transcatheter Cardiovascular Therapeutics - SlideshowBoston Scientific's (BSX) Investor Update On Transcatheter Cardiovascular Therapeutics - Slideshow
seekingalpha.com - October 31 at 5:55 PM
ETFs with exposure to Boston Scientific Corp. : October 31, 2017ETFs with exposure to Boston Scientific Corp. : October 31, 2017
finance.yahoo.com - October 31 at 5:55 PM
Boston Scientific Corp. – Value Analysis (NYSE:BSX) : October 31, 2017Boston Scientific Corp. – Value Analysis (NYSE:BSX) : October 31, 2017
finance.yahoo.com - October 31 at 5:55 PM
Healthy Earnings Growth Makes Boston Scientific (BSX) a BuyHealthy Earnings Growth Makes Boston Scientific (BSX) a Buy
investorplace.com - October 31 at 11:13 AM
Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,500 Shares of StockInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,500 Shares of Stock
www.americanbankingnews.com - October 30 at 5:50 PM
Boston Scientific Corp. breached its 50 day moving average in a Bearish Manner : BSX-US : October 30, 2017Boston Scientific Corp. breached its 50 day moving average in a Bearish Manner : BSX-US : October 30, 2017
finance.yahoo.com - October 30 at 5:50 PM
SunTrust Banks Weighs in on Boston Scientific Corporations Q1 2018 Earnings (BSX)SunTrust Banks Weighs in on Boston Scientific Corporation's Q1 2018 Earnings (BSX)
www.americanbankingnews.com - October 30 at 8:36 AM
Q4 2017 Earnings Estimate for Boston Scientific Corporation (BSX) Issued By Jefferies GroupQ4 2017 Earnings Estimate for Boston Scientific Corporation (BSX) Issued By Jefferies Group
www.americanbankingnews.com - October 30 at 7:56 AM
Boston Scientific Corporation Forecasted to Earn Q4 2017 Earnings of $0.34 Per Share (BSX)Boston Scientific Corporation Forecasted to Earn Q4 2017 Earnings of $0.34 Per Share (BSX)
www.americanbankingnews.com - October 30 at 7:56 AM
Q4 2017 Earnings Forecast for Boston Scientific Corporation Issued By Wedbush (BSX)Q4 2017 Earnings Forecast for Boston Scientific Corporation Issued By Wedbush (BSX)
www.americanbankingnews.com - October 30 at 7:56 AM
Boston Scientific Corporation (BSX) vs. Its Peers Critical SurveyBoston Scientific Corporation (BSX) vs. Its Peers Critical Survey
www.americanbankingnews.com - October 30 at 3:22 AM
Boston Scientific Corporation (BSX) Price Target Increased to $32.00 by Analysts at BMO Capital MarketsBoston Scientific Corporation (BSX) Price Target Increased to $32.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - October 28 at 3:34 PM
 Analysts Expect Boston Scientific Corporation (BSX) Will Announce Quarterly Sales of $2.34 Billion Analysts Expect Boston Scientific Corporation (BSX) Will Announce Quarterly Sales of $2.34 Billion
www.americanbankingnews.com - October 28 at 2:06 AM
Edited Transcript of BSX earnings conference call or presentation 26-Oct-17 12:00pm GMTEdited Transcript of BSX earnings conference call or presentation 26-Oct-17 12:00pm GMT
finance.yahoo.com - October 27 at 7:09 PM
Boston Scientific Corporation (BSX) versus Its Peers Head to Head ReviewBoston Scientific Corporation (BSX) versus Its Peers Head to Head Review
www.americanbankingnews.com - October 27 at 1:24 PM
Boston Scientific (BSX) Q3 2017 Results - Earnings Call TranscriptBoston Scientific (BSX) Q3 2017 Results - Earnings Call Transcript
www.msn.com - October 26 at 10:02 PM
Boston Scientific Corp Profit Climbs 17% In Q3Boston Scientific Corp Profit Climbs 17% In Q3
www.nasdaq.com - October 26 at 4:59 PM

Social Media

Financials

Chart

Boston Scientific Corporation (NYSE BSX) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.